Bradykinesia News and Research

RSS

Neuronal energy deficit may cause Parkinson's disease

Scientists at the University of York have made a significant step forward in isolating the cause of Parkinson's disease in younger adults.

17 Jan 2012

Study finds no support for primary pathogenic role of LBs in PD

The pathology of Parkinson's disease is characterized by a loss of dopamine-producing neurons in the pars compacta of the substantia nigra (SN), an area of the brain associated with motor control, along with the development of α-synuclein (αS) protein in the form of Lewy bodies (LB) in the neurons that survive. The spread of LB pathology is thought to progress along with the clinical course of Parkinson's disease, although recent studies suggest that they are not the toxic cause of cell death.

10 Jan 2012

DOPAL plays key role in killing dopamine neurons which trigger Parkinson's disease: Study

In new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease. The study, published in PLoS One, found that the brain toxin DOPAL plays a key role in killing the dopamine neurons which trigger the illness.

10 Feb 2011

DBS procedure effective for treating Parkinson's disease

Studies have shown that a "brain pacemaker" called deep brain stimulation (DBS) is an effective treatment for Parkinson's disease.

3 Jun 2010

New genetic risk factor for Parkinson's disease identified

An international team of doctors and human geneticists has identified a new genetic risk factor for Parkinson's disease. The institutions involved in the study were the Institute of Human Genetics of Helmholtz Zentrum München and Technische Universität München, the Neurological Clinic of Ludwig-Maximilians-Universität Munich (LMU) and the Mitochondrial Research Group of Newcastle University, Newcastle upon Tyne, UK.

18 Jan 2010

Study reveals interaction of genetic and environmental factors in the pathogenesis of Parkinson's disease

"Our study reveals the interaction of genetic and environmental factors such as dietary habits in the pathogenesis of Parkinson's disease," explained Dr. Matthias Elstner of the Neurological Clinic of LMU and Helmholtz Zentrum M-nchen, lead author of the study.

18 Jan 2010

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009

Discovery provides model for Alzheimer's breakthrough

Sydney researchers have made a major breakthrough that will lead to a greater understanding of the causes of and treatments for neurodegenerative diseases.

24 Sep 2008

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

Rotigotine is a drug not previously approved in the United States. Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease.

10 May 2007

CleveMed receives approval to market motor assessment system

Cleveland Medical Devices has received Food and Drug Administration (FDA) clearance to market Kinesia, a quantitative motor assessment system.

2 May 2007

Alzheimer's disease may be more common than previously recognized

A study published in the January issue of the Annals of Neurology found that neurofibrillary tangles in the substantia nigra, a part of the brain that is subject to cell loss in Parkinson's disease, are associated with gait impairment in older persons with and without dementia.

25 Jan 2006